Business Description
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 71.79 | |||||
Equity-to-Asset | 0.8 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.02 | |||||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -15.5 | |||||
3-Year EPS without NRI Growth Rate | -13.6 | |||||
3-Year FCF Growth Rate | -13.7 | |||||
3-Year Book Growth Rate | -19 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 15.09 | |||||
9-Day RSI | 19.79 | |||||
14-Day RSI | 19.07 | |||||
6-1 Month Momentum % | -92.24 | |||||
12-1 Month Momentum % | -94.38 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 4.85 | |||||
Quick Ratio | 4.85 | |||||
Cash Ratio | 4.75 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.4 | |||||
Shareholder Yield % | -0.59 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -50.78 | |||||
ROA % | -43.43 | |||||
ROIC % | -234.1 | |||||
ROC (Joel Greenblatt) % | -3980.84 | |||||
ROCE % | -48.1 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 1.02 | |||||
Price-to-Tangible-Book | 1.18 | |||||
EV-to-EBIT | 0.09 | |||||
EV-to-EBITDA | 0.09 | |||||
EV-to-Forward-EBITDA | -0.03 | |||||
EV-to-FCF | -0.12 | |||||
Price-to-Net-Current-Asset-Value | 1.21 | |||||
Price-to-Net-Cash | 1.23 | |||||
Earnings Yield (Greenblatt) % | 1035.05 | |||||
FCF Yield % | -78.05 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Ultimovacs ASA Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -0.479 | ||
Beta | 0.32 | ||
Volatility % | 113.77 | ||
14-Day RSI | 19.07 | ||
14-Day ATR (€) | 0.144281 | ||
20-Day SMA (€) | 0.7345 | ||
12-1 Month Momentum % | -94.38 | ||
52-Week Range (€) | 0.4805 - 14.64 | ||
Shares Outstanding (Mil) | 34.41 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 1 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Ultimovacs ASA Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Ultimovacs ASA Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Ultimovacs ASA Frequently Asked Questions
What is Ultimovacs ASA(FRA:7UM)'s stock price today?
When is next earnings date of Ultimovacs ASA(FRA:7UM)?
Does Ultimovacs ASA(FRA:7UM) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |